0 1 7 ) A 8 5 3 -A 9 4 3 analysis established that the average cost of anti-TNF for acute ischemic coronary disease should be US$ 406.52 or with an incidence difference between strategies of 0.032. In addition, for cardiovascular death the average cost should be US$ 290.03 or a difference of 0.071. All the probabilistic sensitivity analyzes performed established an unfavorable relationship of the anti-TNF treatment strategy. These results are robust for deterministic and probabilistic analysis. ConClusions: The findings of the CEA among patients with rheumatoid arthritis for ischemic heart disease when compared to the anti-TNF drug treatment strategy against to the dominant strategy with Dmards after 6 months of drug exposure point to an unfavorable relationship, surpassing the Brazilian Health Ministry's willingness to pay in the year 2015.objeCtives: To estimate and compare the long-term cost per responder based on the Assessment of SpondyloArthritis international Society (ASAS) outcomes following 52 weeks of treatment of ankylosing spondylitis (AS) with secukinumab relative to adalimumab. Methods: The cost per responder for each treatment was estimated by dividing the drug acquisition cost for the course of treatment with its response rate. Drug costs were estimated using the public price approved by Brazilian health authority and the number of doses required for 52 weeks. The longterm response rates were estimated using a matching-adjusted indirect comparison (MAIC) technique based on the data from MEASURE 2 and ATLAS clinical trials of secukinumab and adalimumab, respectively. Results: MAIC analysis showed that ASAS (20, 40 and 5/6) response rates were significantly higher for secukinumab compared to adalimumab at 52 weeks. ASAS 20, ASAS 40 and ASAS 5/6 response rates were 81% vs. 65%, 62% vs. 47%, 74% vs. 55% for secukinumab vs. adalimumab, respectively. The cost per ASAS 20 responder was BRL61,852 vs. BRL147,546, cost per ASAS40 responder was BRL80,407 vs. BRL205,127, whereas, costs per ASAS 5/6 responder was BRL69,240 vs. BRL175,514 for secukinumab vs. adalimumab, respectively. The costs per ASAS (20, 40 and 5/6) responders were about 60% lower for secukinumab compared to adalimumab for all outcomes at 52 weeks. Sensitivity analyses confirmed the robustness of our analysis. ConClusions: The long-term cost per responder for all ASAS outcomes at 52 weeks were consistently lower for secukinumab vs. adalimumab. These findings indicated that it is more efficient to treat AS patients with secukinumab vs. adalimumab. In addition, more AS patients could be effectively treated in Brazil with secukinumab vs. adalimumab with a given budget, due to the cost-offsets.objeCtives: To evaluate effect of baricitinib (BARI) on patient-reported outcomes (PROs) in Latin American (LA)* patients with moderately to severely active rheumatoid arthritis (RA) with limited or no disease-modifying antirheumatic drug (DMARD) and naïve to biologic DMARDs. *LA countries: Argentina, Brazil, and Mexico. Methods: In the global 52-week, dou...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.